Contents
Fully Compliant with Industry Standard

FDA 510(k) Premarket Notification Guidance—Chemistry Appendix B: Determining Critical Micelle Concentration (CMC) by Surface Tension

Prepare a dilution series in the product/device medium, measure surface tension (γ, “gamma”) at each concentration, and plot γ vs log(concentration). Estimate the CMC as the “breakpoint” where the curve changes from a steep slope to a plateau (using the regression method defined in your SOP). Any method you implement must be validated within your quality system.

Who this is for
Regulatory affairs managers, analytical development teams, and formulation scientists supporting contact lens care products with cleaning claims and in‑house formulation control.
Positioning
This page summarizes the FDA-issued approach in Appendix B and describes how Dropometer can support your workflow. It does not replace the official guidance from FDA, establish compliance, or determine the appropriate regulatory pathway.
Last updated
February 17, 2026
Request Dropometer Quote View Official FDA 510(k) Guidance
Written by
abhimanyu
No biography added yet.
Read More
Written By

No biography added yet.

Evidence box

Standard intent (Appendix B, summarized)

The FDA contact lens care products guidance describes a practical method to determine the CMC of a surfactant (or surfactant system) by:

  • prepare a dilution series in the product/device medium: make a surfactant‑free “blank” medium, make a ratio‑matched surfactant stock in that same medium, then dilute the stock with the blank to create the concentration series.,
  • measuring surface tension using a tensiometer at each concentration, and
  • plotting γ vs log(concentration) and using least‑squares regression to locate the breakpoint (slope change) used as the CMC estimate.
Dropometer role in workflow:
  • A repeatable workflow to acquire γ across a dilution series and generate an analyzable curve for CMC estimation.
  • A structured record (series ID, sample IDs, operator, instrument settings, temperature setpoint/actual, and fit‑QC outcomes) to support internal review and submission‑ready reporting. Electronic record acceptability depends on your validation and controls. Device manufacturers must validate the method and define record controls under the applicable quality system.
Primary outputs:
  • Surface tension (γ, “gamma”) at each concentration point, with replicate summary statistics per SOP (standard operating procedure) — for example mean ± SD (standard deviation) or median + IQR (interquartile range)
  • Plot of surface tension (γ) versus log(concentration) (often written log(C); log base defined in your SOP)
  • Estimated CMC (Critical Micelle Concentration): the concentration at the curve “breakpoint” (slope change), with uncertainty if required by your SOP
Calibration requirement:
  • Appendix B describes measurement “by a tensiometer” but does not mandate geometry (ring/plate vs pendant drop). If you use pendant drop, justify equivalence through internal method validation and fit‑quality rules.
  • CMC depends on formulation variables (e.g., pH, tonicity, and other inactive ingredients). CMC results are comparable only when the medium is controlled and documented.
Protocol defaults (starting point):

Defensibility comes from method validation + system suitability + matrix‑matched comparability, not from any single “universal” CMC number. Establish site criteria by surfactant system + medium, including:
• System suitability (reference liquid γ at operating temperature)
• Internal reference surfactant series in a defined, relevant medium (expected ranges for slope/plateau/breakpoint)
• Correlation/bridging if changing geometry (e.g., ring/plate vs pendant drop) or comparing to external labs

Known limitations (risk statements, summarized from the Appendix B context):

Key controls and common limitations to document (Appendix B context):

  • Use a multi‑point dilution series that covers both regions: pre‑CMC slope and post‑CMC plateau.
  • Use a fixed equilibration (“dwell”) time at each concentration point.
  • Run replicates at each point; consider extra replicates near the expected breakpoint if the transition is borderline.
  • Control and record temperature (setpoint and actual).
  • Record any required method inputs (e.g., density for pendant‑drop analysis, if applicable).
  • Retain raw data and calculated outputs for traceability.
  • Estimate the breakpoint using the regression approach defined in your SOP (e.g., two‑region/piecewise regression on γ vs log(C)).
Controls & Data Quality

Measure a reference liquid (system suitability) and/or a matrix‑matched reference surfactant series on a defined frequency. Reject and re‑run points if fit‑QC gates fail. Record temperature (setpoint/actual) and any required density inputs. Maintain a minimum QC checklist (series/sample IDs, lots, operator, settings, fit‑QC outcomes, raw data retention, curve + breakpoint).

How this page was created

Editorial and technical transparency notes for this page.

Transparency Details 3 checklist items
01

Drafting assistance

An initial draft was created with AI assistance (ChatGPT 5.2 Pro).

02

Verification steps

Standard identifiers, units, thresholds, and key procedural claims are checked against cited sources before publication

03

Updates

Reviewed every 12 months or when the underlying standard changes.

Executive summary

Decision question for QA and submission teams: Have we determined and can we defend the surfactant CMC in the actual product medium using a tensiometric dilution‑series approach consistent with Appendix B?

Actionable outcome: A defensible CMC determination helps you (1) set surfactant dosing targets for cleaning performance in the product matrix and (2) trend curve features and breakpoint stability for internal QC.

The Context

Why Appendix B CMC testing is used for contact lens care cleaning claims

Surfactants lower surface tension to support deposit removal. Appendix B treats the CMC as the concentration where the surface tension versus concentration relationship changes slope and approaches a plateau. Because the apparent CMC is medium dependent, the guidance emphasizes running the dilution series in the product/device medium and documenting matrix factors (pH, tonicity, and other inactives) that can shift adsorption and aggregation behavior.

FDA clearance and substantial equivalence in the 510(k) submission process for a medical device submission

CMC testing is typically one dataset within a broader chemistry package for a contact lens care medical device. In the FDA 510(k) pathway—known as premarket notification—a medical device manufacturer submits a premarket submission to the FDA for review so FDA reviewers can assess substantial equivalence.

For many class II products, the sponsor selects an appropriate predicate device and must demonstrate that the device is substantially equivalent to a predicate device that is a legally marketed device (a legally marketed predicate device) for the same indication for use. Stated plainly, the goal is to show the device is substantially equivalent and the device is as safe and effective and effective as the predicate device, without introducing new questions about the effectiveness of the device. The submission must include traceable chemistry evidence sufficient for FDA to determine whether the device can be marketed under clearance (often called marketing clearance).

Not all products follow the same pathway. Some are exempt from premarket notification, and some class iii medical devices require premarket approval through a premarket approval application. Confirm your device classification and current submission format expectations on the FDA website and in applicable FDA program guidance and fda guidance documents.

Documentation note (practical, non‑legal): FDA review performance goals are often described in days (e.g., 90 days), but timelines can extend if FDA requests additional information. Ensure the package is internally auditable so the submission is complete and can be submitted in the format FDA accepts.

Appendix B method summary

What FDA describes

Appendix B outlines a “simple method” that can be implemented as:

  1. Solution 1: Prepare the product medium without surfactants.
  2. Solution 2: Prepare the surfactant system at a reasonable concentration, maintaining the same ratio used in the marketed formulation when multiple surfactants are present.
  3. Solution 3: Prepare a dilution series by diluting Solution 2 with Solution 1.
  4. Measure γ: Measure surface tension for each dilution using a tensiometer at controlled conditions.
  5. Analyze: Plot γ vs log concentration and use least‑squares regression to estimate the CMC from the slope change.

How Dropometer Fits the Workflow

Dropometer supports (and does not replace) the Appendix B workflow by standardizing execution, traceability, and curve analysis.

1

Series execution (device‑medium dilution series)

  • Build/track Solutions 1–3 in the same product/device medium and maintain the same surfactant ratio as used in the final formulation.
  • Assign a series ID and capture preparation notes (pH, tonicity, and relevant inactive ingredients).
2

Tensiometry acquisition (γ at each concentration)

  • Measure γ using your validated geometry (pendant drop if that is your instrument’s method).
  • Enforce fit‑quality gates (stable drop; acceptable residuals; temperature within SOP limits). For pendant‑drop Young–Laplace analysis, temperature and density are controlled inputs and must be recorded.
3

Curve + breakpoint determination (CMC estimate)

  • Generate γ vs log(concentration) and fit two linear regions to estimate the breakpoint concentration as CMC (per SOP).
  • Report replicate statistics and, where required, uncertainty for the breakpoint estimate.

Pendant‑drop tensiometry: γ obtained by fitting the drop shape to the Young–Laplace equation under controlled temperature with documented density inputs.

Validated measurement approach

Independent benchmarking and publication-based validation references.

Benchmark Validation

Our Contact angle and pendant‑drop surface tension methods have been benchmarked against KRÜSS DSA100E reference measurements.

See peer‑reviewed validation

Publication Evidence

Our instruments are referenced in peer‑reviewed journals, theses, and conference publications

Browse the full citations list

Calibration and Correlation plan

Defensible thresholds per material family

Define acceptance criteria by material family (surfactant system + medium) using method capability and historical performance; do not treat the elements below as FDA requirements.

  1. System suitability (reference liquid)
  • Verify the instrument reproduces a reference liquid surface‑tension value at the operating temperature.
  • Set acceptance limits using certified values (when available) plus laboratory precision (e.g., control‑chart action limits).

 

  1. Internal reference surfactant series (matrix‑matched)
  • Maintain a site‑defined reference surfactant series in a defined medium that is relevant to your products.
  • Establish expected ranges for: pre‑CMC slope, post‑CMC plateau, and estimated CMC breakpoint (with an uncertainty model appropriate for your SOP).

 

  1. Method correlation / geometry bridging (if applicable)
  • If replacing a prior ring/plate method or comparing to an external lab, run a correlation study across representative surfactant families and media.
  • Quantify bias and precision and define reportability criteria (e.g., breakpoint agreement within a site‑defined tolerance plus consistent curve morphology).
  • Document fit‑QC rules that govern exclusion, rerun, and reporting.

Example output (illustrative template you will replace with your data)

Below is an example of what a defensible, QC-style summary might look like for one surfactant system + medium. Treat as placeholders not universal thresholds.

Surfactant System S (ratio‑matched) in Product Medium M

Gate Data integrity Curve morphology (γ vs logC) CMC robustness What to do
Pass (Reportable)Temp + required inputs in limits; fit‑QC pass rate acceptableClear slope region + plateau regionRepeat series yields comparable CMC within site criteriaReport γ curve + CMC; trend vs reference series
Monitor (Investigate)Minor deviations; some points rerunTransition region unclear or sparseBreakpoint shifts vs reference seriesExpand range/spacing; increase points; tighten dwell/medium control; rerun near breakpoint
Hold (Not reportable)Temp/input out of limits; fit‑QC failuresNo clear slope/plateau separationCMC not reproducibleRerun affected points/series; document deviations; reassess method controls/fit rules

QC-ready protocol defaults

Starting point, site‑validated

Goal: Generate a curve suitable for Appendix B–style CMC estimation in the product medium.

Sample handling

• Prepare a concentration range spanning pre‑CMC slope → post‑CMC plateau (site‑defined range and number of points).
• Label and track Series ID, sample IDs, lot IDs for all prepared solutions.
• Prepare Solution 1 to match the product/device medium without surfactants.
• Record target pH and tonicity and acceptance ranges per site SOP.
• Record preparation notes (weighing/volumes, mixing order, hold times, storage conditions, deviations).

Setup

• Follow the current official method revision used by your lab for exact parameters and acceptance criteria (this page provides starting‑point defaults, not mandates).
• Record instrument settings used for the run (per current site method revision).
• Input density if required by the measurement approach (e.g., pendant drop).
• Control and record temperature for every point (setpoint and actual).
• Apply a fixed dwell/equilibration time per concentration point (site‑defined) to keep interfacial conditions comparable.

Measurement (baseline method)

• Measure each concentration point using replicates per site SOP (increase replicates near expected breakpoint when separation is borderline).
• At each concentration: equilibrate for the defined dwell time; acquire measurement and calculate γ; perform and document fit‑QC (pass/fail + rationale).
• Retain raw data and calculated outputs; generate γ vs log(concentration); perform stable regression across pre‑CMC and post‑CMC regions; determine the CMC breakpoint per site method.

• Appendix B describes measurement “by a tensiometer” but does not mandate geometry; if using pendant drop, justify equivalence through internal validation and fit‑quality rules.
• CMC depends on matrix variables (pH, tonicity, inactives); comparability requires controlled, documented medium.
• Electronic record acceptability depends on your validation and controls under the applicable quality system.

Decision tree (probabilistic) — triage + rule-out checks

Start: CMC result is unexpected, curve is not reportable, or a QC/submission review flags traceability concerns.

Data integrity issue suspected

Signals:

Temperature and required inputs (e.g., density) out of SOP limits; fit‑QC failures; missing IDs/notes/settings.

Rule-out:

Rerun affected points/series; document deviations; confirm temperature control and required inputs; verify series/sample/lot traceability and raw data retention.

Curve morphology not suitable for breakpoint detection

Signals:

No clear slope region and plateau region; transition region under‑sampled; point‑to‑point noise obscures slope change.

Rule-out:

Adjust concentration range/spacing; increase points; revisit equilibration/dwell time and medium control; add replicates near the transition; confirm fit‑QC rules.

Breakpoint robustness / reproducibility concern

Signals:

Regression regions unstable under SOP‑defined perturbations; replicate series yield non‑comparable CMC outside site acceptance criteria.

Rule-out:

Increase replicates near breakpoint; tighten segment selection rules; reassess fit‑QC gates; compare to matrix‑matched reference series and historical curves.

Medium/matrix shift suspected (comparability failure)

Signals:

pH/tonicity/inactives differ from baseline; curve shape shifts vs historical reference even when instrument controls pass.

Rule-out:

Confirm Solution 1 truly matches the product/device medium without surfactants; verify pH/tonicity targets and acceptance ranges; repeat in controlled, documented medium; assess change management triggers.

Geometry/fit sensitivity suspected (pendant drop or method change)

Signals:

Sensitivity at low γ; results depend strongly on density inputs or image quality; differences vs prior ring/plate or external lab.

Rule-out:

Run geometry‑bridging/correlation study; quantify bias/precision; define reportability criteria; tighten fit‑QC rules and controlled inputs.

Method settings

SOP‑ready starting point

Parameter Recommended Setting Technical Rationale
Geometry Tensiometry for γ across the series (pendant drop if validated for your lab) Appendix B requires surface tension measurement and γ vs log(C) analysis; geometry choice is a validation decision.
Series design Multi‑point dilution series spanning the expected transition region Supports identification of slope and plateau regions and reduces breakpoint instability.
Medium Product/device medium without surfactants used for dilutions Appendix B emphasizes matrix effects; medium control is necessary for comparability.
Temperature Controlled and recorded (site‑defined setpoint) γ is temperature sensitive; recorded values support traceability and comparability.
Equilibration Fixed dwell time per point (site‑defined) Controls adsorption time and improves point‑to‑point comparability.
Replicates Replicates per point; increased near breakpoint (site‑defined) Improves confidence in the breakpoint region and supports uncertainty estimates.
Fit‑QC gates Predefined acceptance limits for drop stability, edge detection, and residuals Prevents reporting of non‑physical fits and supports auditability.
Analysis Two‑line regression (piecewise) on γ vs log(C), with SOP‑defined segment selection rules Aligns with Appendix B’s slope‑change concept while making the decision rule explicit and reproducible.

Interpretation

CMC • γ vs log(concentration) • breakpoint

γ at each concentration point (replicate‑summarized): The traceable measurement basis of the curve; summarize per SOP (mean ± SD or median + IQR) and retain raw data.
γ vs log(concentration) curve morphology: A reportable curve should show a pre‑CMC slope region and a post‑CMC plateau region under controlled medium and conditions.
Estimated CMC breakpoint (slope change) via regression: CMC is estimated from the breakpoint between the fitted regions; robustness depends on range/spacing/replicates and explicit segment‑selection rules.
Traceability + fit‑QC status: Fit‑QC pass/fail outcomes, temperature setpoint/actual, and required inputs (e.g., density for pendant drop) support auditability and comparability across runs.

Business impact — Before/After Dropometer

Metric Before Dropometer With Dropometer
Traceability Ad hoc records; harder internal review Structured records (series IDs, settings, fit‑QC outcomes, raw data retention).
Curve usability Curves sometimes not regression‑stable Workflow emphasizes range/spacing, dwell, replicates, and fit‑QC gates for analyzable curves.
Rework / reruns Late discovery of missing controls Built‑in data quality checks reduce non‑reportable runs.
Change management Method changes hard to defend Geometry bridging + reference series + explicit reportability rules.

Instant ROI Snapshot

Calculate your savings in real time.

Result

≈0
hrs/month saved
≈$0
/month ROI

Where do these numbers come from? i You enter your current total time per test (dispense + record + analyze + save). The calculator assumes that our Dropometer reduces that workflow to ~1.1 minutes per test (dispense + capture + automated fit + export). Time saved per test = max(0, your time − 1.1 min). Monthly hours saved = (monthly tests × minutes saved per test) ÷ 60, and monthly savings = hours saved × labor rate.

Common pitfalls and limitations

Medium mismatch: Running the series in water instead of the product medium can misstate CMC because matrix variables shift adsorption and aggregation behavior.
Temperature drift: Small temperature changes shift γ; control and record temperature.
Pendant‑drop sensitivity: At low γ, Young–Laplace fitting is more sensitive to density inputs and image quality; treat these as controlled inputs with SOP acceptance limits.
Overclaiming “compliance”: Appendix B describes an approach; defensibility comes from execution, validation, and traceable records.
Change management: Reassess curve comparability when there are formulation or process changes that could shift matrix effects.

Legal note (no certification claim)

This page summarizes alignment considerations with the FDA guidance for contact lens care products and Appendix B’s described approach to CMC determination by surface tension. It does not confer FDA endorsement, does not certify compliance, and does not replace the official guidance from FDA or your quality system requirements. Follow the current official guidance from FDA and the consensus standard revision used by your laboratory for exact parameters.

Request Dropometer Quote View Official FDA 510(k) Guidance

Report a correction

Spotted an issue in this summary? Send a correction request and our team will review it.

Correction Request

We work hard to keep this standards summary accurate and up to date. If you spot an error (wrong revision/year, missing requirement, incorrect interpretation, or broken link), tell us and we'll review it.

Contact us to report a correction

References

1. FDA - Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products (May 1, 1997), Chem-Appendix B: Cleaning Effectiveness-Determination of CMC (surface tension vs log concentration
2. FDA - Guidance landing page: “Contact Lens Care Products: Premarket Notification (510(k)) Guidance” (FDA’s current thinking statement and access point)
3. FDA Recognized Consensus Standards - ISO 4311 (1979), “Determination of critical micellization concentration… by measurement of surface tension with a plate, stirrup or ring” (FDA recognition listing)

Download Experiment